Compare Stocks: ABCL, EXEL, BMRN, and HALO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$12.29 +15.8%	$7.38	$2.74 ▼ $12.48	$3.76B	1.2	6.31 million shs	6.84 million shs
BMRN BioMarin Pharmaceutical	$65.89 +1.3%	$60.85	$49.26 ▼ $70.98	$12.75B	0.24	2.08 million shs	389,470 shs
EXEL Exelixis	$56.21 +3.0%	$54.29	$33.76 ▼ $57.57	$13.95B	0.44	2.68 million shs	657,289 shs
HALO Halozyme Therapeutics	$108.99 +0.3%	$83.94	$61.22 ▼ $109.55	$12.36B	0.85	1.87 million shs	462,647 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-6.27%	-5.27%	+99.81%	+100.57%	+141.69%
BMRN BioMarin Pharmaceutical	-2.44%	-2.36%	+9.67%	+23.05%	+11.08%
EXEL Exelixis	+0.87%	+4.26%	-1.48%	+9.14%	+41.21%
HALO Halozyme Therapeutics	+0.43%	+5.48%	+32.60%	+58.09%	+51.27%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$12.29 +15.8%	$7.38	$2.74 ▼ $12.48	$3.76B	1.2	6.31 million shs	6.84 million shs
BMRN BioMarin Pharmaceutical	$65.89 +1.3%	$60.85	$49.26 ▼ $70.98	$12.75B	0.24	2.08 million shs	389,470 shs
EXEL Exelixis	$56.21 +3.0%	$54.29	$33.76 ▼ $57.57	$13.95B	0.44	2.68 million shs	657,289 shs
HALO Halozyme Therapeutics	$108.99 +0.3%	$83.94	$61.22 ▼ $109.55	$12.36B	0.85	1.87 million shs	462,647 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-6.27%	-5.27%	+99.81%	+100.57%	+141.69%
BMRN BioMarin Pharmaceutical	-2.44%	-2.36%	+9.67%	+23.05%	+11.08%
EXEL Exelixis	+0.87%	+4.26%	-1.48%	+9.14%	+41.21%
HALO Halozyme Therapeutics	+0.43%	+5.48%	+32.60%	+58.09%	+51.27%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.71	Moderate Buy	$12.83	4.45% Upside
BMRN BioMarin Pharmaceutical	2.75	Moderate Buy	$88.83	34.82% Upside
EXEL Exelixis	2.30	Hold	$50.07	-10.92% Downside
HALO Halozyme Therapeutics	2.62	Moderate Buy	$91.20	-16.32% Downside

Current Analyst Ratings Breakdown

Latest ABCL, EXEL, BMRN, and HALO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/19/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$98.00
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$54.00
8/18/2026	BMRN BioMarin Pharmaceutical	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/18/2026	BMRN BioMarin Pharmaceutical	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$60.00 ➝ $59.00
8/18/2026	EXEL Exelixis	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Perform	$54.00
8/17/2026	BMRN BioMarin Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$82.00 ➝ $88.00
8/17/2026	BMRN BioMarin Pharmaceutical	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$105.00 ➝ $111.00
8/14/2026	HALO Halozyme Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy (B) ➝ Buy (B-)
8/11/2026	BMRN BioMarin Pharmaceutical	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C-) ➝ Sell (D)
8/11/2026	EXEL Exelixis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (B) ➝ Buy (A-)
8/11/2026	ABCL AbCellera Biologics	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$12.00 ➝ $30.00

(Data available from 8/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$75.13M	50.14	N/A	N/A	$3.23 per share	3.80
BMRN BioMarin Pharmaceutical	$3.22B	3.96	$2.82 per share	23.38	$31.68 per share	2.08
EXEL Exelixis	$2.32B	6.00	$3.15 per share	17.86	$8.06 per share	6.97
HALO Halozyme Therapeutics	$1.40B	8.86	$4.81 per share	22.67	$0.42 per share	259.49

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.41M	-$0.54	N/A	N/A	N/A	-248.83%	-17.49%	-12.36%	11/5/2026 (Estimated)
BMRN BioMarin Pharmaceutical	$348.90M	$0.37	178.00	12.20	0.48	2.14%	5.32%	3.69%	10/26/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	17.70	15.11	1.61	35.33%	42.17%	31.76%	11/3/2026 (Estimated)
HALO Halozyme Therapeutics	$316.89M	$3.35	32.52	11.77	0.43	24.86%	260.98%	23.91%	11/2/2026 (Estimated)

Latest ABCL, EXEL, BMRN, and HALO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	BMRN BioMarin Pharmaceutical	$0.95	$1.20	+$0.25	$0.23	$932.03 million	$989.71 million
8/6/2026	Q2 2026	HALO Halozyme Therapeutics	$1.79	$2.28	+$0.49	$1.90	$402.28 million	$481.00 million
8/5/2026	Q2 2026	ABCL AbCellera Biologics	-$0.1640	-$0.18	-$0.0160	-$0.18	$7.85 million	$4.05 million
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
BMRN BioMarin Pharmaceutical	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
HALO Halozyme Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	12.77	12.77
BMRN BioMarin Pharmaceutical	0.56	2.39	1.32
EXEL Exelixis	N/A	3.46	3.38
HALO Halozyme Therapeutics	13.50	2.71	2.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
BMRN BioMarin Pharmaceutical	98.71%
EXEL Exelixis	85.27%
HALO Halozyme Therapeutics	97.79%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.40%
BMRN BioMarin Pharmaceutical	0.68%
EXEL Exelixis	2.60%
HALO Halozyme Therapeutics	2.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	500	306.61 million	219.53 million	Optionable
BMRN BioMarin Pharmaceutical	3,221	193.57 million	192.26 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
HALO Halozyme Therapeutics	390	113.50 million	110.66 million	Optionable

ABCL, EXEL, BMRN, and HALO Headlines

Recent News About These Companies

Paradigm Capital Management Inc. NY Invests $783,000 in Halozyme Therapeutics, Inc. $HALO

August 25 at 5:44 AM | marketbeat.com

Halozyme Therapeutics (NASDAQ:HALO) Reaches New 12-Month High - What's Next?

August 24 at 4:39 PM | marketbeat.com

NeoGenomics, Inc. (NEO) Hits Fresh High: Is There Still Room to Run?

August 24 at 10:17 AM | zacks.com

Halozyme Therapeutics: Running Through 2027

August 24 at 7:51 AM | seekingalpha.com

Vise Technologies Inc. Takes $743,000 Position in Halozyme Therapeutics, Inc. $HALO

August 24 at 5:20 AM | marketbeat.com

William Blair Investment Management LLC Acquires New Holdings in Halozyme Therapeutics, Inc. $HALO

August 22 at 6:32 AM | marketbeat.com

Allworth Financial LP Acquires New Shares in Halozyme Therapeutics, Inc. $HALO

August 22 at 3:06 AM | marketbeat.com

HALO Stock Rises 36% in a Month: Here's What You Should Know

August 21, 2026 | zacks.com

Great Lakes Advisors LLC Purchases Shares of 36,039 Halozyme Therapeutics, Inc. $HALO

August 21, 2026 | marketbeat.com

Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares

August 20, 2026 | insidertrades.com

Aurora Investment Counsel Takes Position in Halozyme Therapeutics, Inc. $HALO

August 20, 2026 | marketbeat.com

Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 20,000 Shares of Stock

August 19, 2026 | marketbeat.com

Add These 4 GARP Stocks to Your Portfolio to Receive Handsome Returns

August 19, 2026 | zacks.com

Diversify Advisory Services LLC Invests $2.77 Million in Halozyme Therapeutics, Inc. $HALO

August 19, 2026 | marketbeat.com

Foster & Motley Inc. Invests $2 Million in Halozyme Therapeutics, Inc. $HALO

August 19, 2026 | marketbeat.com

Halozyme Appoints Dannielle Appelhans to Board of Directors

August 18, 2026 | tipranks.com

Halozyme Appoints Dannielle Appelhans to its Board of Directors

August 18, 2026 | prnewswire.com

Halozyme Therapeutics (NASDAQ:HALO) Reaches New 52-Week High - What's Next?

August 18, 2026 | marketbeat.com

Halozyme Earnings Call Highlights Surging Royalties, Raised Outlook

August 17, 2026 | tipranks.com

Horizon Investment Services LLC Buys Shares of 28,793 Halozyme Therapeutics, Inc. $HALO

August 17, 2026 | marketbeat.com

Chase Investment Counsel Corp Buys New Stake in Halozyme Therapeutics, Inc. $HALO

August 17, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL, EXEL, BMRN, and HALO Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$12.30 +1.70 (+15.98%)

As of 01:23 PM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

BioMarin Pharmaceutical NASDAQ:BMRN

$65.93 +0.86 (+1.32%)

As of 01:23 PM Eastern

BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. BioMarin Pharmaceutical Inc. has license and collaboration agreements with Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners, Inc. The company was incorporated in 1996 and is headquartered in San Rafael, California.

Exelixis NASDAQ:EXEL

$56.22 +1.67 (+3.06%)

As of 01:23 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Halozyme Therapeutics NASDAQ:HALO

$109.04 +0.40 (+0.36%)

As of 01:23 PM Eastern

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABCL, EXEL, BMRN, and HALO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABCL, EXEL, BMRN, and HALO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABCL, EXEL, BMRN, and HALO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL, EXEL, BMRN, and HALO Company Descriptions

AbCellera Biologics NASDAQ:ABCL

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

Halozyme Therapeutics NASDAQ:HALO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ABCL, EXEL, BMRN, and HALO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ABCL, EXEL, BMRN, and HALO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ABCL, EXEL, BMRN, and HALO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ABCL, EXEL, BMRN, and HALO Company Descriptions

AbCellera Biologics NASDAQ:ABCL

BioMarin Pharmaceutical NASDAQ:BMRN

Exelixis NASDAQ:EXEL

Halozyme Therapeutics NASDAQ:HALO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools